Gaurav Munj 2022-03-04T06:42:16+00:00 CREATING SHAREHOLDER VALUE Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases March 19, 2026 Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment March 2, 2026 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results View All Press Releases View All Events January 12, 2026 at 8:15 AM PST 44th Annual J.P. Morgan Healthcare Conference May 28, 2025 Biohaven R&D Day at Yale School of Management September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEOUntitled Document VIDEOSplay videoINTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEYx play videoInterview with CEO Vlad Coric M.D. on CNBC’s Mad Moneyxplay videoDiseases related to glutamate dysregulationx
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases March 19, 2026 Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment March 2, 2026 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results View All Press Releases View All Events January 12, 2026 at 8:15 AM PST 44th Annual J.P. Morgan Healthcare Conference May 28, 2025 Biohaven R&D Day at Yale School of Management September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEOUntitled Document VIDEOSplay videoINTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEYx play videoInterview with CEO Vlad Coric M.D. on CNBC’s Mad Moneyxplay videoDiseases related to glutamate dysregulationx
March 19, 2026 Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
March 2, 2026 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast